Leadership

Our Leaders

Leadership Image

Ed Seguine

Chief Executive Officer

As Chief Executive Officer (CEO), Ed Seguine brings more than twenty years of experience as a clinical technology executive at big pharma and start-up organizations to the Clinical Ink team. Mr. Seguine joined Clinical Ink in late 2009 with the goal of creating a company that would eliminate problems caused by current paper-based processes and technologies.

+

Prior to joining Clinical Ink, he served as General Manager, Trial Planning at Medidata Solutions, where he managed acquisition integration activities and product positioning prior to the company’s IPO. He also served as CEO of Fast Track Systems, where he oversaw the turnaround process and established early commercial successes for a novel product that became the rationale for acquisition by Medidata Solutions. Prior to Fast Track, Mr. Seguine was a founding manager of the Eli Lilly & Co. venture capital funds, e.Lilly and Lilly Bioventures, focusing on technology and biotech and device companies. Mr. Seguine has also been intimately involved with key industry initiatives, including CDISC and eClinical Forum. He is a frequent presenter at industry events and publishes regularly. Mr. Seguine earned a master of business administration from Indiana University-Bloomington and a bachelor’s degree in finance from Brigham Young University.

-
Leadership Image

Doug Pierce

President & Co-Founder

Doug Pierce co-founded Clinical Ink in 2007 to revolutionize clinical trials by eliminating the complexities and costs associated with paper-based data capture processes. In his role as President and Co-Founder, Mr. Pierce brings more than twenty years of experience in digital forms technology and mobile data capture to lead the strategic direction, development and evolution of Clinical Ink’s eSource Suite.

+

Doug Pierce co-founded Clinical Ink in 2007 to revolutionize clinical trials by eliminating the complexities and costs associated with paper-based data capture processes. In his role as President and Co-Founder, Mr. Pierce brings more than twenty years of experience in digital forms technology and mobile data capture to lead the strategic direction, development and evolution of Clinical Ink’s eSource Suite.

-
Leadership Image

Kirk McPoyle

Chief Commercial Officer

As Chief Commercial Officer, Kirk McPoyle brings twenty-five years of experience in pharmaceutical and healthcare management to his role. Mr. McPoyle leads all Clinical Ink global sales activities to drive market adoption of the company’s industry-leading eSource and patient engagement products and solutions.

+

Mr. McPoyle joined Clinical Ink from Acurian, a patient recruitment organization where, as Senior VP of Business Development, he was responsible for leading the commercial team to sales and implementation excellence. During his tenure, he created and implemented all commercial strategies, including those for customer approach, pricing, proposals and contracting. Prior to Acurian, Mr. McPoyle held several roles at IMS Health, a leading provider of business intelligence for the pharmaceutical and healthcare industry. As VP of Commercial Operations for the Americas, he was responsible for executing the commercial strategy across the Americas and overseeing the sales operations group and the development and orchestration of the organization’s customer loyalty program. Prior to IMS Health, Mr. McPoyle held roles of increasing responsibility in sales, national account management and marketing, as well as senior management positions at TAP Pharmaceuticals.

-
Leadership Image

Jonathan Andrus

Chief Business Officer

As Chief Business Officer, Jonathan Andrus leads Clinical Ink’s solution management and compliance teams to help sponsors and CROs better leverage eSource, eCOA and ePRO data. With more than twenty years of experience, Mr. Andrus brings extensive expertise developing eClinical services that integrate data and technology to help life science companies optimize study execution. At Clinical Ink, Mr. Andrus is responsible for P&L across Clinical Ink’s products and services, and he is also focused on building relationships and forging strategic partnerships with sponsors, CROs, regulatory bodies and clinical research professionals.

+

Mr. Andrus joined Clinical Ink from BioClinica where he led the eClinical Solutions Group to develop their current service offerings, including data management, quality management, implementation services and IWRS. Prior to BioClinica, Mr. Andrus worked in pharmaceutical consulting and with CROs focused on quality, data management and validation. An active thought leader, blogger and presenter, Jonathan served as chair of the Society for Clinical Data Management (SCDM) in 2008 and 2013 and currently serves as the society’s Treasurer. He is also an active member of DIA (North American Advisory Council and Annual Conference Data/Data Standards Track Chair) and ASQ. He earned his bachelor’s and master’s degrees from Temple University’s College of Liberal Arts and Graduate School of Pharmacy and is a Certified Quality Auditor (CQA) and Certified Clinical Data Manager (CCDM®).

-
Leadership Image

Scott Miltenberger

Chief Financial Officer

As Chief Financial Officer, Scott Miltenberger leads Clinical Ink’s accounting, business planning and global financial operations. Mr. Miltenberger brings more than twenty years of financial management and technology industry experience, primarily in executive roles leading strategic global financial operations.

+

Prior to joining Clinical Ink, Mr. Miltenberger was Chief Financial Officer for GPX Enterprises (GPX), a private equity firm focused on the sponsorship, development and management of selected investments, where he helped lead the company through a period of rapid growth. Prior to GPX, Mr. Miltenberger served as CFO for Elemica, a cloud-based software services company, where he led the company’s financial strategy and capital raising initiatives and was instrumental in the organization’s M&A activities. Prior to Elemica, he served as the founding CFO for a venture-backed healthcare services company and held a senior financial role at Novacare Employee Services, where he helped position the company for its IPO. Mr. Miltenberger began his career at Deloitte & Touche LLP. In addition to being a Certified Public Accountant (CPA), Mr. Miltenberger holds a master of business administration in finance from Villanova University and a bachelor’s degree in economics and business from Lafayette College. He is active in many local business and youth sports organizations.

-

Our Board

Vern Davenport

Partner

Vern Davenport brings more than thirty years of executive experience in building and transforming healthcare technology and service companies. Before joining NovaQuest, Mr. Davenport was CEO and Board Member at Medfusion, a leader in healthcare consumerism technology where he was instrumental in the carve-out of the company from Intuit and the return of its core portal solution to a market leadership position. Operationally, he created a culture that earned a Best Places to Work award from Triangle Business Journal. In less than twelve months, the company developed and released two new products in patient payments and consumer patient record integration leveraging both cloud and mobile technologies.

+

Prior to Medfusion, Mr. Davenport was Chairman and CEO of Medquist and leader in transcription services before and after the privatization of the company. As Chairman and CEO, Mr. Davenport facilitated a transformation of the business through the acquisition of a speech technology company, rebranding the company M*Modal and leading the take private process that resulted in the sale of the business to One Equity Partners. Mr. Davenport’s previous experience also includes his time as President of Allscripts, CEO of Misys Healthcare, GM and EVP of Kodak Health Group (now Carestream Health) and his time in executive leadership roles at Siemens Shared Medical Systems. Mr. Davenport began his career at IBM, where he spent eleven years in sales, sales leadership and executive management positions. Mr. Davenport received a master of business administration from East Carolina University as well as a bachelor of science in business administration. Mr. Davenport currently serves on the East Carolina Board of Trustees as well as the WakeMed Health and Hospitals Board.

-

Michael Sorensen

Partner

Michael Sorensen brings more than fifteen years of investment experience and is a member of the Investment Committee at NovaQuest Private Equity. He is responsible for transaction origination, investment policy, fundraising, investor relations and the day-to-day management of NovaQuest Private Equity. In addition, he directs the private equity team in acquisitions, divestitures and oversight of portfolio companies.

+

Prior to NovaQuest, Mr. Sorensen was Director at BlackRock’s private equity group, responsible for making investment decisions in a wide variety of geographies and industries, including healthcare, technology and consumer and retail, among others. He also held a variety of board seats while at the firm. Prior to BlackRock, Mr. Sorensen worked at Sorenson Capital (no familial relation), a mid-market private equity firm based in Salt Lake City. Similar to his current role, he analyzed private companies in a wide range of industry sub sectors and geographies. Mr. Sorensen also worked as a consultant for L.E.K. Consulting in Los Angeles, where he worked closely with clients’ senior management on projects that included asset optimization, strategic planning and customer segmentation, primarily in the healthcare and media industries. Mr. Sorensen received a master of business administration from the Wharton School at the University of Pennsylvania, a master of public administration from Harvard University and a bachelor of science in economics from Brigham Young University.

-

Jeff Williams

Currently Jeff is CEO of MindPath Care Centers (formerly Carolina Partners in Mental Health), one of the largest private-equity backed outpatient mental and behavioral practices in the country. He has served in this capacity since mid-2018.

+

Prior Jeff was CEO of Clinipace Worldwide a contract research organization (CRO) which he co-founded in 2003 as an e-clinical software business. In 2009 he pivoted the company to a full service CRO and launched an M&A strategy that included 6 acquisitions over 6 years growing to more than 900 employees in 25 countries. He grew the business from zero to $100M in revenue by 2015. Today it is one of the top 15 CROs globally. Prior to founding Clinipace Worldwide, Jeff held several executive-level positions within the life sciences and software industries. One of the more interesting non-healthcare stops was as CEO of NextAudio, an early pioneer in Internet-based services which was precisely what Pandora is today. Additionally, Jeff was a co-founder of HealthMatics, one of the first electronic medical records (EMR) software providers, which was sold to A4 Health and later acquired by Allscripts. Prior to these technology endeavors Jeff spent 10 years at Ciba (now Novartis) and two years at Glaxo Wellcome. During this period, he pioneered some of the earliest direct-to-consumer advertising campaigns within the industry. Jeff also currently serves on the Board of Directors for Cathedral Corporation, a leader in print and electronic data output services and Clinical Ink, a leading innovator in clinical research technology platforms. Jeff has a Bachelor of Science degree in Chemistry from the University of Tampa. In 2007, Jeff was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry.

-

Matt King

Matt King oversees the Fund’s investment process, including identifying potential investments, due diligence, investment structuring, syndicate leadership, portfolio management and dispositions. Within the FCA Funds, Mr. King has previously served as a member and President of the general partner for FCA IV and a member of the general partner for FCA III, serving on its investment committee.

+

Mr. King has more than thirty-five years of business experience, the last seventeen of which have been focused exclusively in the venture capital industry. He has participated in over fifty-five venture capital and private equity investments since 1992 and has served as lead investor in twenty-two transactions for FCA III, FCA IV, V and VI. In addition to serving on the Board of Directors at Clinical Ink, he also serves on the Board of Directors of Vericred, StudioNow, MediQuire and KeraFAST. Mr. King previously served as a Vice President of Third National Bank and its successor, SunTrust Bank, as Chairman, President and CEO of Radar Business Systems, Inc. and as Regional Vice President of Radar’s successor company, U.S. Office Products, Inc. He also is a Founder and served as Chairman, President and CEO of MyOfficeProducts, Inc., an FCA III portfolio company. Mr. King currently serves as a Director of Truxton Trust Company, Director of Studio Tenn Theatre Company, Director of Wake Forest University Health Sciences, Trustee of Wake Forest University and as an Elder of Christ Presbyterian Church.

-

Diana Nole

Diana Nole is the CEO of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry serving more than 170 countries and operations worldwide.

+

Before joining Wolters Kluwer, Ms. Nole served as President for the Digital Medical Solutions Division of Carestream Health. In this role, she oversaw all operations for the $1 billion provider of healthcare equipment, software and services with R&D sites globally. She led the successful integration of acquisitions, which boosted the breadth and depth of the portfolio. The product development activities under her direction delivered breakthrough products with substantial customer workflow improvements, resulting in significant revenue growth and #1 customer satisfaction ratings. She joined Carestream Health in 2007. Previously Ms. Nole held multiple leadership roles at Eastman Kodak in its Healthcare Information Technology Solutions group. She started at Kodak in 1987 as Worldwide Logistics Supervisor/Systems Analyst. Ms. Nole holds a master of business administration from the Simon School of Business, University of Rochester, and received her bachelor of arts, magna cum laude, in math and computer science from the State University of New York.

-

Richard Malcolm

Richard Malcolm is currently a partner in Bingham Associates, a management consulting company focused on the clinical trials industry.

+

Prior to this role, Mr. Malcolm served for over eight years as CEO of Acurian, Inc., a venture backed company in the clinical trials space. In 2013, he led the sale of Acurian to PPD, a leading CRO. Before joining Acurian, Mr. Malcolm led a long career in the pharmaceutical industry. He served as VP of Business Development for ICON Clinical Research, another leading CRO; as VP and General Manager of SmithKline’s Clinical Trials Center, a central laboratory that is now owned by Quest Laboratory; as COO of The Medicines Company, a now public start-up pharmaceutical company; and as President of Neutris Pharmaceuticals. He has also held a variety of product marketing positions with Glaxo SmithKline that ranged from Product Manager to Group Director. Mr. Malcolm has a bachelor of science in microbiology from the University of Michigan and a doctor of philosophy in pharmacology from the University of Southern California.

-

Our Partners

Discover more from Clinical Ink
Contact the source of better clinical trials today.
Request a platform demo or more information.